NasdaqGS:RARE

Stock Analysis Report

Executive Summary

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States, Europe, and internationally.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Ultragenyx Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RARE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.1%

RARE

-5.7%

US Biotechs

-11.2%

US Market


1 Year Return

-17.5%

RARE

3.0%

US Biotechs

4.1%

US Market

Return vs Industry: RARE underperformed the US Biotechs industry which returned 3% over the past year.

Return vs Market: RARE underperformed the US Market which returned 4.1% over the past year.


Shareholder returns

RAREIndustryMarket
7 Day-6.1%-5.7%-11.2%
30 Day4.7%0.06%-9.5%
90 Day40.6%-1.0%-5.4%
1 Year-17.5%-17.5%3.9%3.0%6.2%4.1%
3 Year-36.8%-36.8%11.4%8.3%30.3%21.9%
5 Year-5.9%-5.9%-4.1%-8.6%55.0%38.0%

Price Volatility Vs. Market

How volatile is Ultragenyx Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ultragenyx Pharmaceutical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RARE ($55.74) is trading below our estimate of fair value ($116.54)

Significantly Below Fair Value: RARE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RARE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RARE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RARE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RARE is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (2.9x).


Next Steps

Future Growth

How is Ultragenyx Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

47.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RARE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RARE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RARE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RARE's revenue (34.3% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: RARE's revenue (34.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: RARE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Ultragenyx Pharmaceutical performed over the past 5 years?

-24.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RARE is currently unprofitable.

Growing Profit Margin: RARE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RARE is unprofitable, and losses have increased over the past 5 years at a rate of -24.3% per year.

Accelerating Growth: Unable to compare RARE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RARE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (37%).


Return on Equity

High ROE: RARE has a negative Return on Equity (-61.6%), as it is currently unprofitable.


Next Steps

Financial Health

How is Ultragenyx Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: RARE's short term assets ($851.0M) exceed its short term liabilities ($103.3M).

Long Term Liabilities: RARE's short term assets ($851.0M) exceed its long term liabilities ($378.4M).


Debt to Equity History and Analysis

Debt Level: RARE is debt free.

Reducing Debt: RARE has not had any debt for past 5 years.


Balance Sheet

Inventory Level: RARE has a low level of unsold assets or inventory.

Debt Coverage by Assets: RARE's debt is not covered by short term assets (assets are -1.1976999512769E+17x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RARE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RARE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Ultragenyx Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RARE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RARE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RARE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RARE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RARE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Emil Kakkis (59yo)

9.8yrs

Tenure

US$4,845,627

Compensation

Dr. Emil D. Kakkis, MD, Ph.D. has been the Chief Executive Officer and President of Ultragenyx Pharmaceutical Inc. since April 2010. Dr. Kakkis founded Ultragenyx in April 2010. He served as Scientific Adv ...


CEO Compensation Analysis

Compensation vs Market: Emil's total compensation ($USD4.85M) is about average for companies of similar size in the US market ($USD4.93M).

Compensation vs Earnings: Emil's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Emil Kakkis
President9.8yrsUS$4.85m5.15% $167.3m
Shalini Sharp
CFO & Executive VP7.8yrsUS$2.08m0.14% $4.5m
Karah Parschauer
General Counsel & Executive VP3.7yrsUS$2.04mno data
Camille Bedrosian
Chief Medical Officer & Executive VP2.1yrsUS$4.85m0.0021% $69.5k
Theodore Huizenga
VP, Corporate Controller & Principal Accounting Officer5.9yrsno data0.017% $548.6k
Dennis Huang
Chief Technical Operations Officer & Executive VP4.8yrsUS$4.24m0.015% $497.3k
Danielle Keatley
Senior Director of Investor Relations & Corporate Communications0yrsno datano data
Thomas Kassberg
Chief Business Officer & Executive VP8.3yrsUS$2.33m0.13% $4.2m
Cordelia Leonard
Senior Vice President of Regulatory Affairs0yrsno datano data
Vimal Srivastava
Senior Vice President of Business Development & Alliance Management1.9yrsno datano data

5.3yrs

Average Tenure

54yo

Average Age

Experienced Management: RARE's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Emil Kakkis
President9.8yrsUS$4.85m5.15% $167.3m
Daniel Welch
Non-Executive Chairman4.7yrsUS$563.18k0.012% $378.5k
Lars Ekman
Independent Director3.9yrsUS$532.68k0.012% $378.5k
Clay Siegall
Independent Director6.1yrsUS$534.18k0.012% $378.5k
Matthew Fust
Independent Director6.1yrsUS$550.68k0.020% $659.0k
Shehnaaz Suliman
Independent Director1.1yrsno datano data
Deborah Dunsire
Independent Director2.8yrsUS$526.68k0.0084% $273.3k
Michael Narachi
Independent Director4.9yrsUS$535.68k0.012% $378.5k
William Aliski
Independent Director9.1yrsUS$545.68k0.28% $9.1m

4.9yrs

Average Tenure

59yo

Average Age

Experienced Board: RARE's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.


Top Shareholders

Company Information

Ultragenyx Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ultragenyx Pharmaceutical Inc.
  • Ticker: RARE
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.246b
  • Shares outstanding: 57.89m
  • Website: https://www.ultragenyx.com

Number of Employees


Location

  • Ultragenyx Pharmaceutical Inc.
  • 60 Leveroni Court
  • Novato
  • California
  • 94949
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RARENasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2014
UP0DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014
0LIFLSE (London Stock Exchange)YesCommon StockGBUSDJan 2014
RARE *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 2014

Biography

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX201, a factor VIII gene therapy program for the treatment of hemophilia A; and GTX-102, an antisense oligonucleotide for the treatment of angelman syndrome. In addition, the company is developing UX701 that is in preclinical development for Wilson disease; UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/29 03:29
End of Day Share Price2020/02/28 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.